Navigation Links
The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
Date:6/13/2016

TEL AVIV, Israel, June 13, 2016 /PRNewswire/ --

Therapix (OTC: THXBY) (TASE: THXBY.TA), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that five internationally renowned experts, from Israel and the world, have joined its scientific board and team of consultants. The new experts will join Prof. Raphael Mechoulam, who identified the active compound in cannabis, THC, on the advisory board, and Dr. Yafit Stark, a vice president at Teva and a member of the Company's Board of Directors. Such experts will assist the Company by providing counsel, planning and executing the clinical trials for which the Company is preparing.

The experts joining the Company include:

Prof. James Leckman, a child psychiatrist, psychiatrist and physician at Yale University. Dr. Leckman is a reputable child psychiatrist and patient-oriented clinical researcher. He served as Director of the Child Study Center at Yale for over two decades. His colleagues have chosen him as one of the best doctors in America. Prof. Leckman is one of the prominent and notable international experts in the field of research and treatment of Tourette syndrome and movement disorders, and is the author of hundreds of publications in books and leading journals.

Prof. Kirsten Müller-Vahl, Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy of the Hannover Medical School, Germany. An expert in neurology and an adult psychiatrist, who has been working for many years in a clinic specializing in movement disorders. Since 1997 and until 2003, she was the recipient of an award from the German government for clinical research related to Tourette syndrome. In the course of the past 18 years, Prof. Müller-Vahl has studied more than 1,200 adults and children suffering from Tourette and has served as Head of a Tourette syndrome outpatient department since 1995. Since 1994, she has been serving as a member of the scientific advisory board of the German Tourette-Syndrome Association. Prof. Müller-Vahl is the world's leading researcher in the field of cannabinoid-use in treating patients with Tourette syndrome.

Prof. Michael Davidson, Professor of Psychiatry, served as Chief Psychiatrist at the Department of Psychiatry of the Sheba Medical Centre Tel-Hashomer between 2001 and 2007, and currently serves, inter alia, as Chairman of the Stuckinski Centre for Alzheimer's Disease Research in Ramat Gan. He holds a professorship at the Sackler School of Medicine Tel Aviv University and at the Mount Sinai School of Medicine in New York. Prof. Davidson is considered an international expert on Alzheimer's Disease and is the author of approximately 300 publications in scientific literature. He is also the editor of European Neuropsychopharmacology.

Prof. Avi Weizman, Professor of Psychiatry at the Sackler School of Medicine Tel Aviv University, Head of the Laboratory of Biological Psychiatry at the Felsentein Medical Research Center and Director of the Center and Head of Geha Mental Health Center's Research Unit. After earning his MD, he pursued a postgraduate fellowship in both Child and Adult Psychiatry at Tel Aviv University. Since graduating, he held several academic, research, clinical and administrative positions at both Tel Aviv University and the Geha Mental Health Center. Prof. Weizman is an international expert in psychiatry and neuroscience and is the author of 5 books and more that 650 publications in scientific literature.

Dr. Michael Bloch, graduated the Yale University School of Medicine and completed his residency in adult and child psychiatry at Yale. Dr. Bloch serves as Chief Resident at Yale's Clinical Neuroscience Research Unit. His fields of research are concentrated on the study of Tourette syndrome, obsessive-compulsive disorder and trichotillomania across the life span. His research focuses on developing better treatments for children and adults in such situations, and examining predictions of long-term outcomes, with an emphasis on neuroimaging.

Dr. Elran Haber, Therapix's CEO, stated that "we welcome the joining of the revered team of experts, and believe, that in light of their scientific achievements, proficiency and vast accumulated experience, their joining will contribute to the promotion of the Company's operations and the advancement of its business and scientific objectives".

About Therapix 

Therapix is an Israeli pharma company specializing in the development and commercialization of approved drugs that are based on cannabinoid molecules. The Company is listed on the Tel Aviv Stock Exchange and is also traded over-the counter (OTC) in the United States. The Company is engaged in the development of a drug based on cannabinoids and the entourage technology for treating Tourette syndrome, and is preparing for the development of a cannabinoid-based drug for treating impairments in cognitive functioning (including preliminary stages of Alzheimer's disease). The Company's Chairman is Dr. Ascher Shmulewitz and Dr. Elran Haber is its CEO.

For further details, Goldfinger Communications, Irit Radia, +972-546699311 irit@goldfingercom.com


'/>"/>
SOURCE Therapix
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Gamida Cell Announces $4.4 Million Grant from the Israeli Government
2. Oramed to Present at Oppenheimer Annual Israeli Conference
3. Israeli Start-up That Treats Knee Cartilage Injuries Raises $15M for U.S. Pivotal Clinical Trial
4. RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments
5. RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage
6. Untold News, an American Non-Profit, Awards $10,000 (U.S.) Each to Israeli Inventors of a Cancer Bullet, a Metal Ligament Prosthesis, and a Bendable Plastic Touch Screen Display In First Annual Ceremony
7. CareFusion To Invest $100 Million In Israeli Infusion Pump Maker
8. Alaska Structures Delivers $3.5 Million Dollar Mobile Field Hospital to Israeli Defense Forces to Increase Medical Preparedness
9. Boston MedTech Advisors Enters Into 50th Engagement with Israeli Life Sciences Companies
10. Israeli Medical Device Company FlowSense Acquired by Baxter
11. Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... 2019 , ... As the healthcare environment evolves, the ASCP ... laboratory professionals and residents on the forefront of the profession, as well as ... Renowned Speakers Covering Crucial Topics , On September 11, Her Royal Highness Princess ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... assisted living options, has announced the Best Assisted Living Communities in New ... amenities, resident satisfaction, affordability and more.     , AssistedLiving.org used a unique selection ...
(Date:7/13/2019)... ... July 12, 2019 , ... ... formed to address the critical business and legal issues facing the ever-changing health ... created a highly-focused group combining the experience of its health care and restructuring/bankruptcy ...
Breaking Medicine Technology:
(Date:7/13/2019)... ... July 14, 2019 , ... Dr. Rupa Jolly, dentist and ... New Orleans Advocate's A-List of Most Influential New Orleanians in 2019. She joins more ... other newsmakers that have made an impact on the New Orleans community. , Combining ...
(Date:7/13/2019)... ... July 12, 2019 , ... ... and CUBIO Innovation Center , sponsored by Hangzhou Investment Promotion Bureau, Fox ... June 2, 2019. , The conference attracted Fosun Pharmaceuticals, WuXi Biologics, Kelun Pharmaceutical, ...
(Date:7/11/2019)... ... July 11, 2019 , ... The ... resources with a range of features to further advance their mission of delivering ... in manufacturing quality medicines for patients worldwide. The latest additions include a new ...
(Date:7/10/2019)... ... July 10, 2019 , ... ... treatment, Shady Grove Fertility (SGF) remains committed to its core mission ... Throughout the month of July, the practice will host six in-person seminars and ...
(Date:7/9/2019)... ... July 09, 2019 , ... Leading healthcare digital transformation platform ... Cancer Institutes – Clinical Research Innovation (AACI-CRI) annual meeting, held in Chicago, to ... analysis. As the leading provider of clinical research technology solutions, Forte continues to ...
Breaking Medicine News(10 mins):